Neumora shares surge 12.95% premarket after RBC upgrades to Outperform with $7 target, citing undervalued obesity/Parkinson’s pipeline.

Neumora Therapeutics (NMRA) surged 12.95% in premarket trading following RBC Capital Markets upgrading the stock to "outperform" from "sector perform," raising its price target to $7 from $4. The upgrade cited Neumora’s undervalued pipeline in obesity, Parkinson’s disease, and cardiometabolic indications, highlighted by preclinical data showing 19% weight loss with NMRA-215 as a monotherapy and 26% when combined with semaglutide. RBC noted the company’s expanding focus beyond neurology and a market capitalization of $374.28 million that has not yet reflected its potential in the NLRP3 inhibitor class. The upgrade aligns with broader positive sentiment, including a Guggenheim "buy" rating with a $14 price target and Stifel’s raised $3 target, all underscoring growing confidence in Neumora’s therapeutic pipeline and upcoming 2026 data milestones.